A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)

被引：0
|
作者：
O'Cearbhaill, Roisin [1 ]
Sill, Michael [2 ]
Duong, Hoa [3 ]
Waggoner, Steven [4 ]
Grisham, Rachel [1 ]
Backes, Floor [5 ]
Mannel, Robert [6 ]
Tanyi, Janos [7 ]
Powell, Matthew [8 ]
Mathews, Cara [9 ]
Ghamande, Sharad [10 ]
Mcnally, Leah [11 ]
Olawaiye, Alexander [12 ]
Bender, David [13 ]
Duska, Linda [14 ]
Lankes, Heather [15 ]
Zamarin, Dmitriy [16 ]
Schilder, Russell [17 ]
Bookman, Michael [18 ]
Aghajanian, Carol [1 ]
机构：
[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[2] NRG Oncol Stat & Data Management Ctr, Biostat & Bioinformat Dept, Buffalo, NY USA
[3] Kaiser Permanente Sacramento, Hematol Oncol, Sacramento, CA USA
[4] CWRU Case Comprehens Canc Ctr, Gynecol Oncol, Cleveland, OH USA
[5] Ohio State Univ, Comprehens Canc Ctr, Gynecol Oncol, Columbus, OH USA
[6] Univ Oklahoma, Hlth Sci Ctr, Obstet & Gynecol, Oklahoma City, OK USA
[7] Univ Penn, Abramson Canc Ctr, Obstet & Gynecol, Philadelphia, PA 19104 USA
[8] Washington Univ, Gynecol Oncol, St Louis, MO 63110 USA
[9] Women & Infants Hosp Rhode Isl, Obstet & Gynecol, Providence, RI USA
[10] Georgia Cares Minor Underserved NCORP, Gynecol Oncol, Augusta, GA USA
[11] Duke Canc Inst, Gynecol Oncol, Durham, NC USA
[12] UPMC Hillman Canc Ctr, Gynecol Oncol, Pittsburgh, PA USA
[13] Univ Iowa, Obstet & Gynecol, Iowa City, IA USA
[14] Univ Virginia, Gynecol Oncol, Canc Ctr, Charlottesville, VA USA
[15] NRG Oncol Biospecimen Bank Columbus, Translat Sci Operat, Columbus, OH USA
[16] Icahn Sch Med Mt Sinai, Hematol Oncol, New York, NY 10029 USA
[17] Thomas Jefferson Univ, Gynecol Med Oncol, Philadelphia, PA 19107 USA
[18] Kaiser Permanente Northern Calif, Gynecol Oncol, San Francisco, CA USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期
关键词：
D O I：
10.1136/ijgc-2023-IGCS.5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO005LBA
引用
收藏
页码：A4 / A4
页数：1
相关论文
共 50 条
  • [21] The outcome of patients with platinum-resistant/refractory ovarian cancer treated with the combination of pegylated liposomal doxorubicin and gemcitabine
    Galic, V.
    Boulay, R.
    Thomas, M.
    Miller, R.
    Gillenwater, C.
    Chen, C.
    Martino, M.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S48 - S48
  • [22] Efficacy and Toxicity of Gemcitabine and Pegylated Liposomal Doxorubicin in Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
    Karaoglu, Aziz
    Arslan, Ulku Yalcintas
    Ozkan, Metin
    Kalender, Mehmet Emin
    Alici, Suleyman
    Coskun, Ugur
    Gumus, Mahmut
    Celenkoglu, Gokhan
    Er, Ozlem
    Sevinc, Alper
    Buyukberber, Suleyman
    Alkis, Necati
    Benekli, Mustafa
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (01) : 63 - 66
  • [23] A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC)
    Ferrandina, G.
    Lorusso, D.
    Pignata, S.
    Breda, E.
    Savarese, A.
    Nardi, M.
    Scaltriti, L.
    Ludovisi, M.
    Scambia, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [25] A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Shoji, Tadahiro
    Takatori, Eriko
    Omi, Hideo
    Kagabu, Masahiro
    Honda, Tatsuya
    Futagami, Masayuki
    Yokoyama, Yoshihito
    Kaiho, Michiko
    Tokunaga, Hideki
    Otsuki, Takeo
    Takano, Tadao
    Yaegashi, Nobuo
    Kojimahara, Takanobu
    Ohta, Tsuyoshi
    Nagase, Satoru
    Soeda, Shu
    Watanebe, Takafumi
    Nishiyama, Hiroshi
    Sugiyama, Toru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (02) : 355 - 361
  • [26] A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Tadahiro Shoji
    Eriko Takatori
    Hideo Omi
    Masahiro Kagabu
    Tatsuya Honda
    Masayuki Futagami
    Yoshihito Yokoyama
    Michiko Kaiho
    Hideki Tokunaga
    Takeo Otsuki
    Tadao Takano
    Nobuo Yaegashi
    Takanobu Kojimahara
    Tsuyoshi Ohta
    Satoru Nagase
    Shu Soeda
    Takafumi Watanebe
    Hiroshi Nishiyama
    Toru Sugiyama
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 355 - 361
  • [27] Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
    Hamanishi, Junzo
    Takeshima, Nobuhiro
    Katsumata, Noriyuki
    Ushijima, Kimio
    Kimura, Tadashi
    Takeuchi, Satoshi
    Matsumoto, Koji
    Ito, Kimihiko
    Mandai, Masaki
    Nakai, Hidekatsu
    Sakuragi, Noriaki
    Watari, Hidemichi
    Takahashi, Nobutaka
    Kato, Hidenori
    Hasegawa, Kosei
    Yonemori, Kan
    Mizuno, Mika
    Takehara, Kazuhiro
    Niikura, Hitoshi
    Sawasaki, Takashi
    Nakao, Sari
    Saito, Toshiaki
    Enomoto, Takayuki
    Nagase, Satoru
    Suzuki, Nao
    Matsumoto, Takashi
    Kondo, Eiji
    Sonoda, Kenzo
    Aihara, Satomi
    Aoki, Yoichi
    Okamoto, Aikou
    Takano, Hirokuni
    Kobayashi, Hiroshi
    Kato, Hisamori
    Terai, Yoshito
    Takazawa, Akira
    Takahashi, Yusuke
    Namba, Yoshinobu
    Aoki, Daisuke
    Fujiwara, Keiichi
    Sugiyama, Toru
    Konishi, Ikuo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (33) : 3671 - +
  • [28] PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    Genestie, Catherine
    Balleyguier, Corinne
    Ciccolini, Joseph
    Paci, Angelo
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Pegylated liposomal doxorubicin in partially platinum-sensitive, platinum-resistant, or platinum-refractory ovarian cancer: a prospective study
    Zhang, Ying
    Yuan, Zhen
    Zhang, Guo-Nan
    Li, Qing-Shui
    Cui, Man-Hua
    Cheng, Wen-Jun
    Meng, Yuan-Guang
    Wu, Xiao-Hua
    Yue, Ying
    Wang, Li
    Hou, Jian-Qing
    Li, Chang-Zhong
    Qu, Peng-Peng
    Sun, Li-Xin
    Tao, Guang-Shi
    Li, Gui-Ling
    Chen, Ya-Qing
    Ren, Fang
    Cao, Dong-Yan
    Shen, Keng
    ONCOLOGIST, 2024,
  • [30] Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
    Lee, Elizabeth K.
    Xiong, Niya
    Cheng, Su-Chun
    Barry, William T.
    Penson, Richard T.
    Konstantinopoulos, Panagiotis A.
    Hoffman, Mark A.
    Horowitz, Neil
    Dizon, Don S.
    Stover, Elizabeth H.
    Wright, Alexi A.
    Campos, Susana M.
    Krasner, Carolyn
    Morrissey, Stephanie
    Whalen, Christin
    Quinn, Roxanne
    Matulonis, Ursula A.
    Liu, Joyce F.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 72 - 78
12345